Criticised pricing policies
In the third part of a short series, managers tell Investment Week which value plays still look attractive after a strong run this year.
Tides change for India and China
2016 saw several blow-ups for large drug companies
New products, strong finances and robust growth were the main talking points at JP Morgan's recent healthcare conference in San Francisco. There were positive signals regarding the fundraising climate, as well as the strength of innovation within the...
Opportunities in a number of sectors
Valentine's Day special
'Secure growth companies could be toppled by turnaround stories'
Likes healthcare and technology
Set to start trading on Friday 2 December
Rallied following Clinton defeat
'Shock Trump victory would lead to discounts widening'
Headlines and politics are driving healthcare. We see the outcome of the US election in a little over a week's time as a factor to guide investors within the sector - and not as a reason to avoid the sector overall.
Sister for BB Biotech trust
Clinton vowed to tackle drug prices
Possible pricing changes
Four funds for global themes
Latest roundup by QuotedData
The UK healthcare sector is a major beneficiary of EU R&D funding, free-movement of scientists, and a regulatory framework that expedites product approvals across the continent, writes Quilter Cheviot's Amish Patel.
Trump and Clinton fight for presidency
The airline industry is one of the safest in the world, which always seems a fairly ironic statement given some of the air disasters that have made the news in recent years.
Deadline of 27 June
Easy to become 'despondent' over Japan
Following the crescendo of the European sovereign debt crisis in 2011, scepticism plagued investors across the continent, leaving the economy in a fragile, lethargic state.